Please assess the completion status of the following clinical trial:

Trial Title: Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Health subjects aged 18-59 years, who have been completed two-dose regimen of inactive SARS-CoV-2 vaccine in the past 3-6 months, or received one dose of inactive SARS-CoV-2 vaccine in the past 1-3 months.~* The subject can provide with informed consent and sign informed consent form (ICF).~* The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the 6-month follow-up of the study.~* Axillary temperature ≤ 37.0℃.~* Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of immunization.~Exclusion Criteria:~* have the medical history or family history of convulsion, epilepsy, encephalopathy and psychosis.~* be allergic to any component of the research vaccines, or used to have a history of hypersensitivity or serious reactions to vaccination.~* women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months.~* have acute febrile diseases and infectious diseases.~* have severe chronic diseases or condition in progress cannot be controlled.~* congenital or acquired angioedema / neuroedema~* have the history of urticaria 1 year before receiving the investigational vaccine.~* have asplenia or functional asplenia.~* have thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection).~* have needle sickness.~* have the history of immunosuppressive therapy, anti-allergy therapy, cytotoxic therapy or inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and acute corticosteroid therapy without dermatitis) over the past 6 months.~* have received blood products within 4 months before injection of investigational vaccines.~* under anti-tuberculosis treatment.~* not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social or other conditions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- heterologous boost arm with Ad5 vectored vaccine (Type: EXPERIMENTAL): Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster of recombinant SARS-CoV-2 Ad5 vectored vaccine after 3\~6 months.
- homogeneous boost arm with inactive vaccine (Type: ACTIVE_COMPARATOR): Subjects who have been primed with two doses of inactive SARS-CoV-2 vaccine will receive a booster dose of inactive SARS-CoV-2 vaccine after 3\~6 months.
- heterologous regimen with Ad5 vectored vaccine (Type: EXPERIMENTAL): Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of recombinant SARS-CoV-2 Ad5 vectored vaccine after 1\~3 months.
- homogeneous regimen arm with inactive vaccine (Type: ACTIVE_COMPARATOR): Subjects who have been primed with one dose of inactive SARS-CoV-2 vaccine will receive one dose of inactive SARS-CoV-2 vaccine after 1\~3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete